We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+15.06%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1B
AUM Growth
+$73.5M
Cap. Flow
-$38M
Cap. Flow %
-3.79%
Top 10 Hldgs %
34.85%
Holding
100
New
15
Increased
28
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$17.5M
2
MDT icon
Medtronic
MDT
+$16.5M
3
TMO icon
Thermo Fisher Scientific
TMO
+$16M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$11.2M
5
RPRX icon
Royalty Pharma
RPRX
+$7.69M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$24.6M
2
LLY icon
Eli Lilly
LLY
+$12.8M
3
CVS icon
CVS Health
CVS
+$11.6M
4
ELV icon
Elevance Health
ELV
+$11.6M
5
MCK icon
McKesson
MCK
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IGMS
76
DELISTED
IGM Biosciences
IGMS
$1.66M 0.17%
200,000
– –
NTLA icon
77
Intellia Therapeutics
NTLA
$1.68B
$1.52M 0.15%
50,000
– –
SYK icon
78
Stryker
SYK
$133B
$1.5M 0.15%
+5,000
New +$1.4M
ACHC icon
79
Acadia Healthcare
ACHC
$2.96B
$1.45M 0.14%
+18,624
New +$1.38M
AMGN icon
80
Amgen
AMGN
$226B
$1.3M 0.13%
+4,500
New +$1.23M
TECH icon
81
Bio-Techne
TECH
$11.2B
$1.23M 0.12%
16,000
-26,680
-63% -$1.76M
BRKR icon
82
Bruker
BRKR
$8.58B
$1.18M 0.12%
+16,000
New +$1.03M
PEN icon
83
Penumbra
PEN
$12.8B
$629K 0.06%
+2,500
New +$553K
LUNG icon
84
Pulmonx
LUNG
$97.9M
$319K 0.03%
+25,000
New +$260K
MGTX icon
85
MeiraGTx Holdings
MGTX
$1.21B
$225K 0.02%
32,091
-506,895
-94% -$2.5M
ALLO icon
86
Allogene Therapeutics
ALLO
$725M
– –
-300,000
Closed -$951K
BDX icon
87
Becton Dickinson
BDX
$48.9B
– –
-95,000
Closed -$24.6M
BNTX icon
88
BioNTech
BNTX
$23.3B
– –
-53,000
Closed -$5.76M
EW icon
89
Edwards Lifesciences
EW
$53B
– –
-29,000
Closed -$2.01M
HRMY icon
90
Harmony Biosciences
HRMY
$2.27B
– –
-81,474
Closed -$2.67M
MRNA icon
91
Moderna
MRNA
$23.9B
– –
-30,000
Closed -$3.1M
MRSN
92
DELISTED
Mersana Therapeutics
MRSN
– –
-16,000
Closed -$508K
OM icon
93
Outset Medical
OM
$92.7M
– –
-3,333
Closed -$544K
TXG icon
94
10x Genomics
TXG
$7.63B
– –
-68,000
Closed -$2.81M
VEEV icon
95
Veeva Systems
VEEV
$38.1B
– –
-23,000
Closed -$4.68M
RCM
96
DELISTED
R1 RCM Inc. Common Stock
RCM
– –
-300,000
Closed -$4.52M
OLK
97
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
– –
-166,000
Closed -$2.45M
KRTX
98
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-35,000
Closed -$5.92M
IMGN
99
DELISTED
Immunogen Inc
IMGN
– –
-700,000
Closed -$11.1M
MRTX
100
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-175,000
Closed -$7.62M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2023 Portfolio in Review

As of Q4 2023, Rhenman & Partners Asset Management held 100 positions worth $1B, up 7.9% from $928M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $38M in Q4 2023, closing 15 positions and reducing 32 holdings. Its most notable exit was Becton Dickinson, an estimated $24.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Pfizer worth $16.7M.

  • Rhenman & Partners Asset Management's largest Q4 2023 buy was Pfizer: 580,000 shares worth $16.7M.
  • Rhenman & Partners Asset Management added most to Medtronic in Q4 2023, an estimated $16.5M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2023 reduction was Eli Lilly, cutting an estimated $12.8M.
  • Rhenman & Partners Asset Management fully exited Becton Dickinson in Q4 2023, selling an estimated $24.6M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $1B portfolio in Q4 2023.
  • Rhenman & Partners Asset Management opened 15 new positions and closed 15 in Q4 2023.
  • Rhenman & Partners Asset Management's portfolio value rose 7.9% quarter-over-quarter to $1B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.